Loss of fas expression and function is coupled with colon cancer resistance to immune checkpoint inhibitor immunotherapy

Wei Xiao, Mohammed L. Ibrahim, Priscilla S. Redd, John D. Klement, Chunwan Lu, Dafeng Yang, Natasha Marie Savage, Kebin Liu

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Despite the remarkable efficacy of immune checkpoint inhibitor (ICI) immunotherapy in various types of human cancers, colon cancer, except for the approximately 4% microsatellite- instable (MSI) colon cancer, does not respond to ICI immunotherapy. ICI acts through activating CTLs that use the Fas-FasL pathway as one of the two effector mechanisms to suppress tumor. Cancer stem cells are often associated with resistance to therapy including immunotherapy, but the functions of Fas in colon cancer apoptosis and colon cancer stem cells are currently conflicting and highly debated. We report here that decreased Fas expression is coupled with a subset of CD133 + CD24 lo colon cancer cells in vitro and in vivo. Consistent of the lower Fas expression level, this subset of CD133 + CD24 lo Fas lo colon cancer cells exhibits decreased sensitivity to FasL-induced apoptosis. Furthermore, FasL selectively enriches CD133 + CD24 lo Fas lo colon cancer cells. CD133 + CD24 lo Fas lo colon cancer cells exhibit increased lung colonization potential in experimental metastatic mouse models and decreased sensitivity to tumor-specific CTL adoptive transfer and ICI immunotherapies. Interestingly, FasL challenge selectively enriched this subset of colon cancer cells in microsatellite-stable (MSS) but not in the MSI human colon cancer cell lines. Consistent with the downregulation of Fas expression in CD133 + CD24 lo cells, lower Fas expression level is significantly correlated with decreased survival in patients with human colon cancer. Implications: Our data determine that CD133 + CD24 lo Fas lo colon cancer cells are capable to evade Fas-FasL cytotoxicity of tumor-reactive CTLs and targeting this subset of colon cancer cells is potentially an effective approach to suppress colon cancer immune evasion.

Original languageEnglish (US)
Pages (from-to)420-430
Number of pages11
JournalMolecular Cancer Research
Volume17
Issue number2
DOIs
StatePublished - Feb 1 2019

Fingerprint

Immunotherapy
Colonic Neoplasms
Microsatellite Repeats
Neoplastic Stem Cells
Apoptosis
Immune Evasion
Neoplasms
Adoptive Transfer
Down-Regulation

ASJC Scopus subject areas

  • Molecular Biology
  • Oncology
  • Cancer Research

Cite this

Loss of fas expression and function is coupled with colon cancer resistance to immune checkpoint inhibitor immunotherapy. / Xiao, Wei; Ibrahim, Mohammed L.; Redd, Priscilla S.; Klement, John D.; Lu, Chunwan; Yang, Dafeng; Savage, Natasha Marie; Liu, Kebin.

In: Molecular Cancer Research, Vol. 17, No. 2, 01.02.2019, p. 420-430.

Research output: Contribution to journalArticle

Xiao, Wei ; Ibrahim, Mohammed L. ; Redd, Priscilla S. ; Klement, John D. ; Lu, Chunwan ; Yang, Dafeng ; Savage, Natasha Marie ; Liu, Kebin. / Loss of fas expression and function is coupled with colon cancer resistance to immune checkpoint inhibitor immunotherapy. In: Molecular Cancer Research. 2019 ; Vol. 17, No. 2. pp. 420-430.
@article{4175022df71247c980b9a624a697b03b,
title = "Loss of fas expression and function is coupled with colon cancer resistance to immune checkpoint inhibitor immunotherapy",
abstract = "Despite the remarkable efficacy of immune checkpoint inhibitor (ICI) immunotherapy in various types of human cancers, colon cancer, except for the approximately 4{\%} microsatellite- instable (MSI) colon cancer, does not respond to ICI immunotherapy. ICI acts through activating CTLs that use the Fas-FasL pathway as one of the two effector mechanisms to suppress tumor. Cancer stem cells are often associated with resistance to therapy including immunotherapy, but the functions of Fas in colon cancer apoptosis and colon cancer stem cells are currently conflicting and highly debated. We report here that decreased Fas expression is coupled with a subset of CD133 + CD24 lo colon cancer cells in vitro and in vivo. Consistent of the lower Fas expression level, this subset of CD133 + CD24 lo Fas lo colon cancer cells exhibits decreased sensitivity to FasL-induced apoptosis. Furthermore, FasL selectively enriches CD133 + CD24 lo Fas lo colon cancer cells. CD133 + CD24 lo Fas lo colon cancer cells exhibit increased lung colonization potential in experimental metastatic mouse models and decreased sensitivity to tumor-specific CTL adoptive transfer and ICI immunotherapies. Interestingly, FasL challenge selectively enriched this subset of colon cancer cells in microsatellite-stable (MSS) but not in the MSI human colon cancer cell lines. Consistent with the downregulation of Fas expression in CD133 + CD24 lo cells, lower Fas expression level is significantly correlated with decreased survival in patients with human colon cancer. Implications: Our data determine that CD133 + CD24 lo Fas lo colon cancer cells are capable to evade Fas-FasL cytotoxicity of tumor-reactive CTLs and targeting this subset of colon cancer cells is potentially an effective approach to suppress colon cancer immune evasion.",
author = "Wei Xiao and Ibrahim, {Mohammed L.} and Redd, {Priscilla S.} and Klement, {John D.} and Chunwan Lu and Dafeng Yang and Savage, {Natasha Marie} and Kebin Liu",
year = "2019",
month = "2",
day = "1",
doi = "10.1158/1541-7786.MCR-18-0455",
language = "English (US)",
volume = "17",
pages = "420--430",
journal = "Molecular Cancer Research",
issn = "1541-7786",
publisher = "American Association for Cancer Research Inc.",
number = "2",

}

TY - JOUR

T1 - Loss of fas expression and function is coupled with colon cancer resistance to immune checkpoint inhibitor immunotherapy

AU - Xiao, Wei

AU - Ibrahim, Mohammed L.

AU - Redd, Priscilla S.

AU - Klement, John D.

AU - Lu, Chunwan

AU - Yang, Dafeng

AU - Savage, Natasha Marie

AU - Liu, Kebin

PY - 2019/2/1

Y1 - 2019/2/1

N2 - Despite the remarkable efficacy of immune checkpoint inhibitor (ICI) immunotherapy in various types of human cancers, colon cancer, except for the approximately 4% microsatellite- instable (MSI) colon cancer, does not respond to ICI immunotherapy. ICI acts through activating CTLs that use the Fas-FasL pathway as one of the two effector mechanisms to suppress tumor. Cancer stem cells are often associated with resistance to therapy including immunotherapy, but the functions of Fas in colon cancer apoptosis and colon cancer stem cells are currently conflicting and highly debated. We report here that decreased Fas expression is coupled with a subset of CD133 + CD24 lo colon cancer cells in vitro and in vivo. Consistent of the lower Fas expression level, this subset of CD133 + CD24 lo Fas lo colon cancer cells exhibits decreased sensitivity to FasL-induced apoptosis. Furthermore, FasL selectively enriches CD133 + CD24 lo Fas lo colon cancer cells. CD133 + CD24 lo Fas lo colon cancer cells exhibit increased lung colonization potential in experimental metastatic mouse models and decreased sensitivity to tumor-specific CTL adoptive transfer and ICI immunotherapies. Interestingly, FasL challenge selectively enriched this subset of colon cancer cells in microsatellite-stable (MSS) but not in the MSI human colon cancer cell lines. Consistent with the downregulation of Fas expression in CD133 + CD24 lo cells, lower Fas expression level is significantly correlated with decreased survival in patients with human colon cancer. Implications: Our data determine that CD133 + CD24 lo Fas lo colon cancer cells are capable to evade Fas-FasL cytotoxicity of tumor-reactive CTLs and targeting this subset of colon cancer cells is potentially an effective approach to suppress colon cancer immune evasion.

AB - Despite the remarkable efficacy of immune checkpoint inhibitor (ICI) immunotherapy in various types of human cancers, colon cancer, except for the approximately 4% microsatellite- instable (MSI) colon cancer, does not respond to ICI immunotherapy. ICI acts through activating CTLs that use the Fas-FasL pathway as one of the two effector mechanisms to suppress tumor. Cancer stem cells are often associated with resistance to therapy including immunotherapy, but the functions of Fas in colon cancer apoptosis and colon cancer stem cells are currently conflicting and highly debated. We report here that decreased Fas expression is coupled with a subset of CD133 + CD24 lo colon cancer cells in vitro and in vivo. Consistent of the lower Fas expression level, this subset of CD133 + CD24 lo Fas lo colon cancer cells exhibits decreased sensitivity to FasL-induced apoptosis. Furthermore, FasL selectively enriches CD133 + CD24 lo Fas lo colon cancer cells. CD133 + CD24 lo Fas lo colon cancer cells exhibit increased lung colonization potential in experimental metastatic mouse models and decreased sensitivity to tumor-specific CTL adoptive transfer and ICI immunotherapies. Interestingly, FasL challenge selectively enriched this subset of colon cancer cells in microsatellite-stable (MSS) but not in the MSI human colon cancer cell lines. Consistent with the downregulation of Fas expression in CD133 + CD24 lo cells, lower Fas expression level is significantly correlated with decreased survival in patients with human colon cancer. Implications: Our data determine that CD133 + CD24 lo Fas lo colon cancer cells are capable to evade Fas-FasL cytotoxicity of tumor-reactive CTLs and targeting this subset of colon cancer cells is potentially an effective approach to suppress colon cancer immune evasion.

UR - http://www.scopus.com/inward/record.url?scp=85060934197&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060934197&partnerID=8YFLogxK

U2 - 10.1158/1541-7786.MCR-18-0455

DO - 10.1158/1541-7786.MCR-18-0455

M3 - Article

VL - 17

SP - 420

EP - 430

JO - Molecular Cancer Research

JF - Molecular Cancer Research

SN - 1541-7786

IS - 2

ER -